Search results for " cardiovascular diseases"

showing 10 items of 81 documents

Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observationa…

2018

The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clar…

medicine.medical_specialtySettore MED/09 - Medicina InternaPrognosiEpidemiologyPopulationDiseaseHyperuricemia030204 cardiovascular system & hematologyRisk AssessmentCardiovascular disease; Epidemiology; Uric acid; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid; Internal Medicine; Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetrospective StudieRisk FactorsInternal medicineEpidemiologymedicineInternal MedicineHumansHyperuricemiaRisk factoreducationRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseCardiovascular diseasePrognosisUric AcidchemistryItalyCardiovascular DiseasesResearch DesignUric acidCardiovascular disease; Epidemiology; Uric acidbusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersHumanHigh blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension
researchProduct

RISK OF CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY IN FRAIL AND PRE-FRAIL OLDER ADULTS:RESULTS FROM A META-ANALYSIS AND EXPLORATORY META-REGRESSI…

2017

Frailty is common and associated with poorer outcomes in the elderly, but its role as potential cardiovascular disease (CVD) risk factor requires clarification. We thus aimed to meta-analytically evaluate the evidence of frailty and pre-frailty as risk factors for CVD. Two reviewers selected all studies comparing data about CVD prevalence or incidence rates between frail/pre-frail vs. robust. The association between frailty status and CVD in cross-sectional studies was explored by calculating and pooling crude and adjusted odds ratios (ORs)+/- 95% confidence intervals (CIs); the data from longitudinal studies were pooled using the adjusted hazard ratios (HRs). Eighteen cohorts with a total …

GerontologyAging1303 Biochemistry030204 cardiovascular system & hematologyBiochemistry0302 clinical medicineRisk Factorscardiovascular diseasePrevalenceMedicine030212 general & internal medicineCardiovascular disease; Frailty; Meta-analysis; Aged; Frail Elderly; Humans; Prevalence; Risk Assessment; Risk Factors; Cardiovascular Diseases; Biotechnology; Biochemistry; Aging; Molecular Biology; NeurologyOXIDATIVE STRESSProspective cohort studyELDERLY-PATIENTSPOPULATIONeducation.field_of_studyFrailtyHazard ratioMENASSOCIATION16. Peace & justiceCardiovascular disease3. Good healthMIDLIFE OBESITYNeurologyCardiovascular DiseasesMeta-analysis1305 BiotechnologyRisk assessmentCardiovascular disease; Frailty; Meta-analysis; Aged; Frail Elderly; Humans; Prevalence; Risk Assessment; Risk Factors; Cardiovascular DiseasesBiotechnologymedicine.medical_specialtyWOMENS-HEALTHFrail ElderlyPopulationCardiovascular disease; Frailty; Meta-analysis; Biotechnology; Biochemistry; Aging; Molecular Biology; Neurology610 Medicine & healthfrailtyFrailty Cardiovascular disease Meta-analysisRisk AssessmentArticle03 medical and health sciences1302 AgingInternal medicine1312 Molecular BiologyHumansCORONARY-HEART-DISEASERisk factorFrailty cardiovascular disease meta-analysiseducationMolecular BiologyAgedbusiness.industryAGE FRAILTYOdds ratio10060 Epidemiology Biostatistics and Prevention Institute (EBPI)Confidence intervalmeta-analysisMeta-analysis3121 General medicine internal medicine and other clinical medicine2808 NeurologyFOLLOW-UPbusiness
researchProduct

Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project

2020

The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation …

0301 basic medicineMaleTime FactorsDiseaseUric acid.chemistry.chemical_compound0302 clinical medicineRisk FactorsUric Acid Cardiovascular events epidemiologyEpidemiologyMulticenter Studies as TopicHyperuricemiaStrokeCardiovascular events; Cardiovascular mortality; Uric acid; URRAHMiddle AgedPrognosisObservational Studies as TopicItalyCardiovascular DiseasesResearch DesignFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyCardiovascular mortalityUric acid · Cardiovascular mortality · Cardiovascular events · URRAHContext (language use)Cardiovascular eventHyperuricemiaRisk AssessmentCardiovascular events03 medical and health sciencesURRAHcardiovascular events; cardiovascular mortality; urrah; uric acidPharmacotherapyInternal medicineInternal MedicinemedicineHumansAgedRetrospective Studiesbusiness.industrymedicine.disease030104 developmental biologychemistryHeart failureUric acidbusinessUric acid030217 neurology & neurosurgeryCardiovascular events; Cardiovascular mortality; Uric acid; URRAH; Adult; Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Italy; Male; Middle Aged; Multicenter Studies as Topic; Observational Studies as Topic; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Uric AcidBiomarkers
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

STEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES: AN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS

2021

AIMS:\ud \ud Stem cells are a promising therapy for various medical conditions. The literature regarding their adoption for the clinical care of cardiovascular diseases (CVD) is still conflicting. Therefore, our aim is to assess the strength and credibility of the evidence on clinical outcomes and application of stem cells derived from systematic reviews and meta-analyses of intervention studies in CVD.\ud \ud METHODS and RESULTS:\ud \ud Umbrella review of systematic reviews with meta-analyses of randomized controlled trials (RCTs) using placebo/no intervention as control group. For meta-analyses of RCTs, outcomes with a random-effect p-value< 0.05, the GRADE (Grading of Recommendations Ass…

cardiovascular disease; meta-analysis; randomized controlled trials; stem cells; umbrella review0301 basic medicineUmbrella review.Agingmedicine.medical_specialtyMyocardial InfarctionStem cellsPlaceboBiochemistrylaw.invention03 medical and health sciencesUmbrella review0302 clinical medicineRandomized controlled triallawIntervention (counseling)medicineHumansMeta-analysicardiovascular diseasesMyocardial infarctionIntensive care medicineMolecular BiologyRandomized Controlled Trials as TopicStem cellbusiness.industrymedicine.diseaseCardiovascular diseaseIntervention studiesMeta-analysisCardiovascular diseases030104 developmental biologySystematic reviewAN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS.- Ageing research reviews ss.101257 2021 [Demurtas J. Fanelli G. N. Romano S. L. Solari M. Yang L. Soysal P. Sánchez G. F. L. Grabovac I. Smith L. Zorzi A. et al. -STEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES]NeurologyCardiovascular DiseasesRandomized controlled trialMeta-analysisCardiovascular disease; Meta-analysis; Randomized controlled trials; Stem cells; Umbrella review; Humans; Randomized Controlled Trials as Topic; Stem Cells; Cardiovascular Diseases; Myocardial InfarctionRandomized controlled trialsCardiovascular disease; Stem cells; Umbrella review; Meta-analysis; Randomized controlled trialsStem cellbusiness030217 neurology & neurosurgeryBiotechnology
researchProduct

The magnesium global network (MaGNet) to promote research on magnesium in diseases focusing on covid-19

2021

When the current SARS-CoV-2 pandemic began in early 2020, the global magnesium researcher community came together and noted the striking similarities between COVID-19 risk factors and conditions associated with magnesium deficit state in humans, reasoning that magnesium deficiency could worsen the course of COVID-19 [1-4]. This prompted establishment of a worldwide collaborative network with regular virtual meetings to brainstorm the associations between magnesium and COVID-19. We hypothesize that magnesium deficiency, a common but mostly unrecognized state in modern global societies, could be an important component of the susceptibility to SARS-CoV-2 infection. Consequently, restoring the …

Societies ScientificAgingSupplementationComorbidityMetabolic DiseasesSettore MED/04 - PATOLOGIA GENERALENeoplasmsHypomagnesaemiaCardiovascular DiseaseHumansMagnesiumObesityDisease severityNutritionInflammationPreventionResearchCOVID-19ThrombosisScientificHypermagnesaemiaCongresses as TopicMetabolic DiseaseCardiovascular DiseasesImmune SystemICUThrombosiNeoplasmDisease Susceptibilityhypomagnesaemia hypermagnesaemia inflammation thrombosis prevention disease severity supplementation nutrition ICUSocietiesMagnesium DeficiencyDisease severity; Hypermagnesaemia; Hypomagnesaemia; ICU; Inflammation; Nutrition; Prevention; Supplementation; Thrombosis; Aging; COVID-19; Cardiovascular Diseases; Comorbidity; Congresses as Topic; Disease Susceptibility; Humans; Immune System; Inflammation; Magnesium; Magnesium Deficiency; Metabolic Diseases; Neoplasms; Obesity; Research; Societies ScientificHuman
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

2018

Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available suppleme…

ConsensusFunctional foodsClinical Decision-MakingFood supplementDisease030204 cardiovascular system & hematologyLDL03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalPlasma cholesterolRisk FactorsEnvironmental healthFood supplementsRed yeast riceMedicineAnimalsHumans030212 general & internal medicineCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Clinical Decision-Making; Consensus; Dyslipidemias; Evidence-Based Medicine; Humans; Protective Factors; Risk Factors; Diet Healthy; Dietary Supplements; Functional Food; Risk Reduction BehaviorDyslipidemiasPharmacologyLdl cholesterolHealthyEvidence-Based MedicinePrimary preventionCholesterolbusiness.industryFunctional foodFood supplementation functional foods cholesterol LDL-cholesterol cardiovascular risk primary preventionCholesterol LDLProtective FactorsCardiovascular riskDietCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; PharmacologyYoung ageCholesterolchemistryCardiovascular DiseasesDietary SupplementsLDL cholesterolPosition paperDiet HealthybusinessRisk Reduction BehaviorBiomarkers
researchProduct

Effects of obesity and estradiol on Na+/K+-ATPase and their relevance to cardiovascular diseases

2013

Obesity is associated with aberrant sodium/potassium-ATPase (Na+/K+-ATPase) activity, apparently linked to hyperglycemic hyperinsulinemia, which may repress or inactivate the enzyme. The reduction of Na+/K+-ATPase activity in cardiac tissue induces myocyte death and cardiac dysfunction, leading to the development of myocardial dilation in animal models; this has also been documented in patients with heart failure (HF). During several pathological situations (cardiac insufficiency and HF) and in experimental models (obesity), the heart becomes more sensitive to the effect of cardiac glycosides, due to a decrease in Na+/K+-ATPase levels. The primary female sex steroid estradiol has long been …

estradiol sodium/potassium adenosine triphosphatase obesity cardiovascular diseases
researchProduct

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

2022

Introduction: Inclisiran is a novel posttranscriptional gene silencing therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis by RNA interference and has a potent, dose-dependent, durable effect in lowering LDL-C, and therefore is an effective drug to treat dyslipidemia, reducing the risk for acute cardiovascular (CV) events. It is safe and well-tolerated. Areas covered: This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program. Expert opinion: Data from the clinical trials in the ORION program demonstrated efficacy and safety o…

DrugSmall interfering RNAmedia_common.quotation_subjectHypercholesterolemiaPlaceboBioinformaticsLDLPCSK9RNA interferencemedicineAnimalsHumansPharmacology (medical)Gene SilencingRNA Small InterferingAdverse effectDyslipidemiasmedia_commontherapy.business.industryPCSK9General Medicinemedicine.diseaseClinical trialCardiovascular DiseasesAtherosclerosis inclisiran LDL PCSK9 RNA therapy Animals Cardiovascular Diseases Dyslipidemias Gene Silencing Humans Hypercholesterolemia Proprotein Convertase 9 RNA Small InterferingAtherosclerosiRNAProprotein Convertase 9businessinclisiranDyslipidemiaExpert Opinion on Drug Safety
researchProduct